Venmax Drugs And Pharmaceuticals shareholding pattern

VENMAX

21.86

1.08 (-4.71%)
Last updated on 2 Jun, 2026 | 12:25 IST
Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Venmax Drugs And Pharmaceuticals Shareholding Pattern

  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

13.8%

Mutual Fund

0%

Insurance

0%

Foreign Institutional Investors

0%

Domestic Institutional Investors

0%

Retail

86.2%

Others

0%

Total Promoters
MAR '26
13.8%

Summary

Venmax Drugs And Pharmaceuticals share holding pattern reports the following shareholding: Venmax Drugs And Pharmaceuticals Total Promoters is at 13.80%, Mutual Fund at 0.00%, Insurance at 0.00%, Foreign Institutional Investors at 0.00%, Domestic Institutional Investors at 0.00%, and Retail at 86.20%. This breakdown provides a quick snapshot of ownership distribution for Venmax Drugs And Pharmaceuticals share holding pattern in 2026-27.

Venmax Drugs And Pharmaceuticals FAQs

As of 06-2026, the promoter shareholding in Venmax Drugs And Pharmaceuticals stands at 13.8% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.

The FII and DII shareholding of Venmax Drugs And Pharmaceuticals is 0% and 0% respectively.

The retail shareholding of the Venmax Drugs And Pharmaceuticals is 86.2%.

Changes in shareholding patterns of Venmax Drugs And Pharmaceuticals can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.

Shareholding patterns of Venmax Drugs And Pharmaceuticals are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.

The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost